IPBA

Inflection Point Biomedical Advisors

Inflection Point Biomedical Advisors provides effective strategic advice and implement hands-on, innovative projects in Precision Medicine for the pharmaceutical and diagnostics industry, investment and VC funds as well as to the EU and US governmental agencies.

IPBA is a key collaborator and vital partner of Article25 Capital.

Our mission is to optimize the development, access, implementation and commercial roll-out of clinical Dx globally.

Precision Medicine integration and global implementation services

Underpinned by our vision

Underpinned by our vision

We are focused on the needs of our clients and believe that Precision Medicine (PM) is an expanding business opportunity requiring real time market feedback, change management and evolutionary business models. Also we put our own skin in the game with our investments in the field, driven by our profound knowledge of the markets, and appraisal of the assets from an impact-opportunity angle and the potential to cover unmet needs. IPBA's skills, experience and team are critical components of the expertise and guidance that Article25 Capital can offer portfolio companies and other funds.

A decade of Precision Medicine projects

A decade of Precision Medicine projects

To date, we have worked on over 100 Dx/Rx related projects for leading pharma, biotechs, Dx companies, VC funds, governmental agencies and private foundations. This provides us a critical, real world track record and skills base dedicated to the organizational integration and commercial implementation of PM and Dx services or products into the PM business model and the various market needs.

With a focus on implementation

With a focus on implementation

At IPBA we focus on a number of key implementation infrastructure gaps in PM. Specifically, we have established a global team of PM experts and local connections, built a network of over 500 laboratories, and supported this with an in-house deep lab dynamics knowledge, launching scenarios needs and challenges and commercial launch capability. We have implemented action plans ranging from EQA schemes to dynamic, hands-on workshops to ensure successful Rx and Dx launches.